---
title: "Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/268856072.md"
description: "Biokin Pharmaceutical disclosed for the first time at the 2025 European Society for Medical Oncology Asia Congress (ESMO-Asia) the efficacy data of its self-developed HER2 ADC drug T-Bren in patients with HER2-mutated advanced treated non-small cell lung cancer (NSCLC), with a 12-month progression-free survival rate of 73.5%, demonstrating best-in-class potential"
datetime: "2025-12-07T10:48:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268856072.md)
  - [en](https://longbridge.com/en/news/268856072.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268856072.md)
generator: "portal-rs"
---

# Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%

Biokin Pharmaceutical announced during the oral presentation session at the 2025 European Society for Medical Oncology Asia Congress (ESMO-Asia) the clinical research results of its independently developed flagship product T-Bren (BL-M07D1), a novel HER2 antibody-drug conjugate (HER2 ADC) targeting advanced treated non-small cell lung cancer (NSCLC) with HER2 mutations

### Related Stocks

- [02615.HK](https://longbridge.com/en/quote/02615.HK.md)
- [688506.CN](https://longbridge.com/en/quote/688506.CN.md)

## Related News & Research

- [‘Large tax hikes on the way’: How the global bond rout is boxing in Healey](https://longbridge.com/en/news/297771121.md)
- [Asian Growth Stocks With Strong Insider Ownership](https://longbridge.com/en/news/297731540.md)
- [Nutra Pharma says Pure Raw Supplies gains control with 62.63% voting power after Series B transfer](https://longbridge.com/en/news/297819211.md)
- [Baidu completes dual-primary listing in Hong Kong and Nasdaq](https://longbridge.com/en/news/297602235.md)
- [Baidu shifts Hong Kong listing to dual-primary from secondary listing](https://longbridge.com/en/news/297571992.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**